baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

HSBC Call 3600 TDXP 19.06.2024/ DE000HG7X979 /

2024-06-07 8:27:13 AM	Chg.-0.004	Bid10:00:09 PM	Ask10:00:09 PM	Underlying	Strike price	Expiration date	Option type
0.012EUR	-25.00%	- Bid Size: -	- Ask Size: -	TECDAX	3,600.00 -	2024-06-19	Call

GlobeNewswire 05-14 CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease

GlobeNewswire 01-23 Bluebeam Harnesses the Power of AI and Customer Passion to Drive Innovation in the Built World

GlobeNewswire 2023-12-11 Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune c...

GlobeNewswire 2023-11-07 Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline

GlobeNewswire 2023-09-05 Bluebeam Announces New Executive Leadership Appointments

GlobeNewswire 2018-06-12 Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...

GlobeNewswire 2016-12-20 Medigene announces outlicensing of AAVLP technology

GlobeNewswire 2016-12-13 MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...

GlobeNewswire 2016-12-06 Medigene AG to be included in TecDAX Index

GlobeNewswire 2016-12-06 MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...

GlobeNewswire 2016-12-06 MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016

GlobeNewswire 2016-11-28 MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...

GlobeNewswire 2016-11-17 MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...

GlobeNewswire 2016-11-15 MorphoSys Raises EUR 115 million in Private Placement

GlobeNewswire 2016-11-15 Ad hoc: MorphoSys Raises EUR 115 million in Private Placement

GlobeNewswire 2016-11-15 MorphoSys to Raise Capital via a Private Placement of New Shares

GlobeNewswire 2016-11-15 Ad hoc: MorphoSys to Raise Capital via a Private Placement of New Shares

GlobeNewswire 2016-11-15 MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...

GlobeNewswire 2016-11-14 MorphoSys to Present at Upcoming Investor Conferences

GlobeNewswire 2016-11-08 Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations

GlobeNewswire 2016-11-07 MorphoSys AG Reports Results for the First Nine Months of 2016

GlobeNewswire 2016-11-03 MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...

GlobeNewswire 2016-11-02 MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...

GlobeNewswire 2016-10-28 MorphoSys to Host Q3 2016 Conference Call on November 7, 2016

GlobeNewswire 2016-10-20 MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody

HSBC Call 3600 TDXP 19.06.2024/ DE000HG7X979 /

If you wish to receive reply to your feedback, please provide your email address.